Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma In Situ of the Breast

Abstract

Ductal carcinoma in situ(DCIS), the preinvasive form of infiltrating ductal breast cancer, accounts for 20-30% of breast cancers and is treated surgically. In DCIS, the malignant cells are confined within the basement membrane. DCIS is a local disease, and so an ideal candidate for local therapies. DNA methylation is one mechanism for tumor suppressor gene inactivation. It is an early event in the course of malignant progression. Because methylation is a potentially reversible mechanism for tumor suppressor gene inactivation, it is an intriguing target for molecular therapeutics. Drugs, such as 5-aza-deoxycytidine (DAC), are available that can reverse methylation changes and prevent neoplasia in vivo.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2003
Accession Number
ADA418200

Entities

People

  • Kristin A. Skinner

Organizations

  • University of Southern California

Tags

DTIC Thesaurus Topics

  • Basements
  • Biomedical Research
  • Breast Cancer
  • Carcinoma
  • Diseases And Disorders
  • Electronic Mail
  • Information Operations
  • Membranes
  • Methylation
  • Neoplasms
  • New York
  • Reversible
  • Side Effects
  • Suppressors
  • Test And Evaluation
  • Therapy

Fields of Study

  • Medicine

Readers

  • Cellular and Molecular Pathways of Apoptosis.
  • Oncology and Biomarker-Based Cancer Detection.